Drug Studies in Newborns:: A Therapeutic Imperative

• Autores: George P. Giacoia, Perdita Taylor-Zapata, Anne Zajicek
• Localización: Clinics in Perinatology, ISSN 0095-5108, Vol. 39, Nº. 1, 2012, págs. 11-23
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Although some drugs have been developed for the neonate, drug development for the least mature and most vulnerable pediatric patients is lacking. Most of the drugs are off-label or off-patent and are empirically administered to newborns once efficacy has been demonstrated in adults and usefulness is suspected or demonstrated in the older pediatric population. Few drugs are approved by the Food and Drug Administration for use in this population. The factors that prevent the demonstration of efficacy and safety in the newborn are discussed and a change in the current approach for neonatal drug studies is suggested.